In this issue van Hout and Simoons describe a cost-effectiveness analysis of cardiovascular disease risk reduction by HMG coenzyme reductase inhibitors (statins). This exercise stems from the recommendations of the Netherlands Consensus Committee on Lipid Lowering. Costs of prescriptions and of major medical events (death, acute myocardial infarction, stroke, PTCA and CABG surgery) are consider...